Lilly's oral GLP-1 orforglipron succeeds in Phase 3 trial

Triggering global regulatory submissions this year for the treatment of obesity

Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity

The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity

Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India

Emcure Pharmaceuticals, Sanofi India ink distribution agreement to broaden reach of Sanofi's oral anti-diabetic drugs

FDA approves Bayer’s Finerenone for new indication in patients with HF and LVEF of ?40%

Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,

Biocon gets approval for diabetes drug Liraglutide in India

The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus

Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)

Agilent inaugurates India Solution Center to accelerate innovation

Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets

Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM

The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets

Morepen to launch new fatty lever drug ‘Resmetirom’